Skip to content

EV / sales at other companies

HRO
HarrowHROW
5.7×-0.6×
Zevra Therapeutics, Inc. logo
Zevra Therapeutics, Inc.ZVRA
3.7×-6.9×
XER
Xeris Biopharma Holdings, Inc.XERS
3.6×-1.1×
Ultragenyx Pharmaceutical logo
Ultragenyx PharmaceuticalRARE
2.7×-4.0×
ANI Pharmaceuticals logo
ANI PharmaceuticalsANIP
1.9×-0.5×
Crinetics Pharmaceuticals logo
Crinetics PharmaceuticalsCRNX
206.7×-3,840×

Other financials

Income statement

See full
Revenue$24.3M+40.4%
Gross profit$14.7M+49.4%
Operating income$2.4M+614%
Net income$1.6M+199%
EPS (diluted)$0.05+183%

Balance sheet

See full
Cash & equivalents$19.7M+12.9%
Total debt$31.3M+3.7%
Total equity$30.6M+25.2%
Total assets$97.7M+16.3%

Cash flow

See full
Operating cash flow$7.4M+254%
CapEx$75.0K
Free cash flow$7.3M+251%

Valuation

See full
Market cap$930.79M+156%
Enterprise value$942.39M+150%
P/S10.7×+3.2×

Profitability

See full
Gross margin54.8%-3.7pp
Operating margin-15.1%
Net margin-9.5%-2.7pp
FCF margin17.1%

Returns & leverage

See full
Return on equity-34.2%+0.9pp
Debt / equity-0.2×
Current ratio1.2×-0.8×

Where this comes from

Calculated from Eton Pharmaceuticals, Inc.’s reported figures.

Based on the most recent quarter.

The official record: Eton Pharmaceuticals, Inc.’s 10-Q, filed May 14, 2026, on SEC EDGAR. View the filing →

Ask your AI about Eton Pharmaceuticals, Inc.'s ev / sales.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Eton Pharmaceuticals, Inc.'s EV / sales?
Eton Pharmaceuticals, Inc. (ETON) reported EV / sales of 7.9× in Q1 2026.
How has Eton Pharmaceuticals, Inc.'s EV / sales changed year-over-year?
Eton Pharmaceuticals, Inc.'s EV / sales increased by 5.5% year-over-year, from 7.5× to 7.9×.
What is the long-term trend for Eton Pharmaceuticals, Inc.'s EV / sales?
Over 5 years (2020 to 2025), Eton Pharmaceuticals, Inc.'s EV / sales has grown at a -73.9% compound annual growth rate (CAGR), from 4,777.7× to 5.7×.
What does EV / sales mean?
Enterprise value at the quarter end divided by trailing-twelve-month revenue. A capital-structure-neutral revenue multiple, useful when earnings are negative.